Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 1 to 10 of 65 total matches.

Trilaciclib (Cosela) for Prevention of Chemotherapy-Related Myelosuppression

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
Trilaciclib (Cosela) for Prevention of Chemotherapy-Related Myelosuppression ...
The FDA has approved trilaciclib (Cosela – G1 Therapeutics), a cyclin-dependent kinase (CDK) 4/6 inhibitor, to decrease the incidence of chemotherapy-induced myelosuppression in adults receiving a platinum/etoposide- or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib is the first myeloprotective drug to be approved in the US for administration before chemotherapy.
Med Lett Drugs Ther. 2021 Nov 1;63(1636):174-5 |  Show IntroductionHide Introduction

Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023  (Issue 1677)
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia ...
Eflapegrastim-xnst ((Rolvedon) [Spectrum]; previously called Rolontis), a granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG4, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia.
Med Lett Drugs Ther. 2023 May 29;65(1677):83-4   doi:10.58347/tml.2023.1677b |  Show IntroductionHide Introduction

Tremelimumab (Imjudo) for Metastatic NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023  (Issue 1669)
-based chemotherapy for treatment of metastatic non-small cell lung cancer (NSCLC) in adults ...
The FDA has approved tremelimumab-actl (Imjudo – AstraZeneca), a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody, for use in combination with the programmed death-ligand 1 (PD-L1) blocking antibody durvalumab (Imfinzi) and platinum-based chemotherapy for treatment of metastatic non-small cell lung cancer (NSCLC) in adults with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e31-2   doi:10.58347/tml.2023.1669h |  Show IntroductionHide Introduction

Ryzneuta for Prevention of Febrile Neutropenia

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia. It is the first ...
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia. It is the first nonpegylated, long-acting G-CSF to become available in the US. Two pegylated, long-acting G-CSFs, pegfilgrastim (Neulasta, and biosimilars) and eflapegrastim (Rolvedon), are...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):134-5   doi:10.58347/tml.2024.1709d |  Show IntroductionHide Introduction

Tislelizumab (Tevimbra) for Esophageal Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
or metastatic esophageal squamous cell cancer in adults who received prior systemic chemotherapy that did ...
The FDA has approved tislelizumab (Tevimbra – BeiGene), a programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic esophageal squamous cell cancer in adults who received prior systemic chemotherapy that did not include a programmed death ligand-1 (PD-L1) inhibitor.
Med Lett Drugs Ther. 2024 May 13;66(1702):e85-6   doi:10.58347/tml.2024.1702h |  Show IntroductionHide Introduction

Cemiplimab (Libtayo) for NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
chemotherapy than with chemotherapy alone (21.9 vs 13.0 months). Median progression-free survival was 8.2 ...
The FDA has approved cemiplimab-rwlc (Libtayo – Regeneron), an immune checkpoint inhibitor, for use in combination with platinum-based chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1 aberrations and who are not candidates for surgical resection or chemoradiation. The drug was previously approved for first-line treatment of NSCLC in patients whose tumors have high PD-L1 expression and no genomic tumor aberrations....
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e67-8   doi:10.58347/tml.2023.1674e |  Show IntroductionHide Introduction

Zolbetuximab (Vyloy) for Gastric and Gastroesophageal Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
or GEJ adenocarcinoma, addition of zolbetuximab to standard chemotherapy extended progression-free ...
Zolbetuximab-clzb (Vyloy – Astellas), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, has been approved by the FDA for use in combination with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who have CLDN18.2-positive tumors. It is the first monoclonal antibody to be approved in the US that selectively targets CLDN18.2.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e204-5   doi:10.58347/tml.2024.1717g |  Show IntroductionHide Introduction

Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024  (Issue 1694)
chemotherapy. It is the first immune checkpoint inhibitor to be approved in the US for treatment ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with cisplatin and gemcitabine for first-line treatment of recurrent locally advanced or metastatic nasopharyngeal carcinoma and for use as monotherapy for treatment of recurrent unresectable or metastatic nasopharyngeal carcinoma in adults with disease progression on or after platinum-based chemotherapy. It is the first immune checkpoint inhibitor to be approved in the US for treatment of nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7   doi:10.58347/tml.2024.1694e |  Show IntroductionHide Introduction

Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025  (Issue 1723)
who received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease ...
The FDA has approved datopotamab deruxtecan (Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e41-2   doi:10.58347/tml.2025.1723e |  Show IntroductionHide Introduction

In Brief: Olaparib (Lynparza) for High-Risk Early Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
neoadjuvant or adjuvant chemotherapy. The drug was previously approved for treatment of adults ...
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza – AstraZeneca) has been approved by the FDA for adjuvant treatment of adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who received prior neoadjuvant or adjuvant chemotherapy. The drug was previously approved for treatment of adults with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who received chemotherapy in the neoadjuvant, adjuvant, or metastatic...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e77-8   doi:10.58347/tml.2023.1674j |  Show IntroductionHide Introduction